Reported 1 day ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently viewed as a strong buy by analysts, with Bernstein's William Pickering maintaining a Buy rating and a price target of $95.00, while Evercore ISI's Cory Kasimov set a target of $110.00. The analyst consensus indicates a Strong Buy with a median price target suggesting a potential upside of 70.49%. The company focuses on developing treatments for serious and rare medical conditions.
Source: YAHOO